The Landmark Series: Cancer Vaccines for Solid Tumors
Annals of Surgical Oncology – Immunotherapy has become an integral part of the treatment for solid tumors. Cancer vaccines represent a potentially powerful class of immunotherapeutic agents to…
Related Articles
2024 Most Read Articles | Blood | American Society of Hematology
2024 Most Read Articles | Blood | American Society of Hematology Top Ten Most Read Articles in 2024 Blood is pleased to announce the following…
MaaT013, a pooled fecal allogenic microbiotherapy, for treating refractory GI acute GvHD
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the results of an early access program that used MaaT013, a pooled…
Expanding the genetic landscape of congenital neutropenia: CXCR2 mutations in three families revealed through whole exome sequencing
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Division of Translation Oncology, Department…
Pirtobrutinib Improves PFS in Previously Treated CLL/SLL
Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden
Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD
Drs Camidge and Redman discuss Dr Redman’s role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.
An Overview of the Treatment Landscape for EGFR-mutated NSCLC
A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing…
